Psst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveCLEATUS Webinar: AI for Government Contracting — Free Webinar — Wednesday, July 22 at 2:00 PM EDT

Register Free →

Get CLEATUSFree Trial

Get CLEATUSFree Trial

Search

Top

Back to Contracts

Limited Competition: Clinical and Translational Science Awards (CTSA) Program: Collaborative and Innovative Acceleration Award

Active

Grant

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

General Info

Agency

Department Of Health And Human Services → National Institutes Of HealthView Agency

NAICS

N/A

Place of Performance

Not specified

Set-Aside

NONE

Documents

(0)

No documents available

AI Contract Breakdown

Uniform Contract Format

No contract breakdown available.

Cannot generate Contract Breakdown because no documents were found from this contract's source.

Timeline

PostedJul 20

forecast

Ready to pursue this opportunity?

Start your free trial to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

Show more

AgencyDepartment Of Health And Human Services → National Institutes Of Health

Contacts1 person available

OfficeUS

Organization / Agency

Department Of Health And Human Services → National Institutes Of Health

View Agency Profile

Office AddressUS

Contacts

Division of Clinical Innovation

contact@example.gov

Full Description

Show more

The purpose of the Congressionally mandated Clinical and Translational Science Award (CTSA) Program is to accelerate the translation of scientific discoveries into treatments, diagnostics, and health interventions that improve patient and public health by funding and coordinating a national network of academic medical centers that provide the infrastructure, expertise, training, and collaboration needed to move discoveries from the laboratory into clinical practice and community health. The purpose of the reissuance of the Collaborative and Innovative Acceleration Award for the CTSA Program Notice of Funding Opportunity (NOFO) is to support the collaborative development of innovative approaches, technologies, or models that synergistically enhance the impact of research, advance translational science, and bring more treatments for all people more quickly.

Awards are made under the authorization of Sections 301 and 405 of the Public Health Service Act as amended (42 USC 241 and 284) and under Federal Regulations 42 CFR Part 52 and 2 CFR Part 200.

This is a Forecast for a Limited Competition that will invite application(s) from eligible organization(s) to apply. Please see Eligibility Section for additional information. In accordance with NIH standard peer-review processes, the application(s) will be peer-reviewed, and only meritorious application(s) will be considered for funding.

More opportunities from Department Of Health And Human Services → National Institutes Of Health

Same awarding agency

Limited Competition: Institutional Mentored Research Career Development Program for the Clinical and Translational Science Awards Program

POSTED

DEADLINE

Limited Competition: Ruth L. Kirschstein National Research Service Award (NRSA) Institutional Research Training Grant for the Clinical and Translational Science Awards Program

POSTED

DEADLINE

Limited Competition: Research Education Program for the Clinical and Translational Science Awards Program

POSTED

DEADLINE

Limited Competition: High Impact Specialized Innovation Programs in Clinical and Translational Science

POSTED

DEADLINE

Clinical and Translational Science Award

POSTED

DEADLINE

The Next Generation of the Clinical and Translational Science Awards Program Trial Innovation Network

POSTED

DEADLINE

Elucidation and Validation of the role of Transporters in the Placenta, Lactating Mammary Gland, Developing Gut, and Blood Brain BarrierThe Eunice Kennedy Shriver National Institute of Child Health and Human Development is advancing its mission to improve maternal, fetal, and child health by launching a second phase of the Transporter Elucidation Network, focused on understanding how biological transporters and local metabolic processes regulate exposure to nutrients, medications, microbiome-derived compounds, and environmental chemicals across critical perinatal barriers. This initiative will develop comprehensive multi-barrier frameworks that connect the maternal gut, placenta, lactating mammary epithelium, infant gut, and infant blood-brain barrier, building on prior organ-specific research to create standardized models, resources, and prototype multi-compartment systems that reflect the dynamic interplay of transporters, their polarity, kinetics, and biotransformation capacities during pregnancy, lactation, and infant development. The goal is to deepen mechanistic insights into how these systems influence nutrient delivery, drug distribution, and neurodevelopmental outcomes in early life. This phase will establish community-wide resources to support integrated studies of perinatal exposure, risk assessment, and targeted interventions across linked maternal-fetal-infant systems, while strengthening collaboration among researchers and accelerating the sharing of tools and data. Emphasis is placed on human-based and developmentally relevant models to ensure biological accuracy and translational impact. The effort also aims to cultivate a next-generation workforce skilled in transporter science, fostering innovation in pediatric pharmacology and neonatal health. Authorized under 42 U.S.C. § 241, the initiative is being led by the Obstetric and Pediatric Pharmacology and Therapeutics Branch of NICHD, with inquiries directed to their designated point of contact, and the opportunity was publicly forecasted on July 16, 2026.

Research and Development in Biotechnology (except Nanobiotechnology)

POSTED

DEADLINE

Opportunities for Collaborative Research with the NIH Intramural Research Program (U01 Clinical Trial Optional)The program aims to foster collaborative translational research between NIH intramural scientists and external extramural investigators to accelerate the translation of basic biological discoveries into clinical applications that improve health. It supports high-quality science with the potential to advance understanding of significant disease processes or lead to new diagnostics, therapeutics, or prevention strategies aligned with the priorities of participating NIH Institutes and Centers. The initiative specifically encourages partnerships that leverage the unique resources and expertise available within the NIH intramural research program, enabling extramural researchers to conduct clinical research in collaboration with NIH scientists. This effort is designed to strengthen translational science by bridging the gap between laboratory-based research and clinical implementation through integrated, multidisciplinary teams. The funding opportunity, titled Opportunities for Collaborative Research with the NIH Intramural Research Program (U01 Clinical Trial Optional), is posted by the National Institutes of Health under the Department of Health and Human Services and is forecasted for release on July 16, 2026. It is open to both intramural and extramural investigators and allows for clinical trials as optional components. The primary point of contact for inquiries is the U01 Program team, reachable via email at nihirppartnerships@mail.nih.gov or by phone at 301-496-4121. Additional details and application information can be accessed through the Grants.gov portal at the provided link. The program does not specify a set-aside type, NAICS code, or physical office location, reflecting its national scope and administrative structure under NIH's broader research framework.

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

DEADLINE

Limited Competition: NIMHD Initiative for Improving American Indian and Alaska Native Cancer Outcomes (U19 - Clinical Trial Optional)This opportunity, issued by the National Institutes of Health under the Department of Health and Human Services, is a forecast for a limited competition aimed at advancing research to reduce cancer incidence and mortality among American Indians and Alaska Natives, especially those in rural areas. The initiative, titled Limited Competition: NIMHD Initiative for Improving American Indian and Alaska Native Cancer Outcomes (U19 - Clinical Trial Optional), seeks to support projects focused on prevention, diagnosis, and treatment of cancer with the goal of generating practical, culturally relevant outcomes that directly benefit AI/AN communities and their families. Applications must come from eligible organizations, and proposals will undergo standard NIH peer review, with only meritorious submissions considered for funding. The opportunity is open to clinical trials but does not require them. Interested parties should note that the posting date is July 16, 2026, and inquiries can be directed to the NIMHD DCHPS Scientific Team at nimhddchpsscientificteam@mail.nih.gov.

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

DEADLINE

Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)The National Cancer Institute is soliciting R33 grant applications to support the advanced development and rigorous validation of emerging technologies aimed at advancing cancer research and clinical care. This opportunity is intended for projects that have already addressed major feasibility barriers, as demonstrated by strong preliminary data, but require further refinement, optimization, and technical validation to achieve broad adoption within the scientific community. The focus is on technologies with new or substantially improved capabilities for measuring, analyzing, modeling, or interrogating cancer-related biological systems, including advanced molecular and cellular platforms, multi-omic and spatial profiling methods, next-generation imaging and sensing tools, immuno-engineering approaches, and innovations in biospecimen handling and quality assessment. Proposals must center on cancer-specific applications, and applications that merely apply established technologies to novel biological questions without technological innovation are not eligible. This funding opportunity is part of the NCI’s Innovative Molecular Analysis Technologies Program and explicitly prohibits clinical trials. The goal is to accelerate progress in areas such as cancer biology, early detection, diagnosis, treatment, control, and epidemiology by enabling technologies that offer transformative potential for the research community. Projects must demonstrate clear potential for widespread utility in cancer research while maintaining a tight focus on technical advancement rather than application-specific hypotheses. All applications must be submitted through the designated grants portal, and inquiries should be directed to the IMAT Program Contact provided. The opportunity was posted in July 2026 and is open to applicants seeking to bridge the gap between initial innovation and scalable adoption in cancer science.

Research and Development in Biotechnology (except Nanobiotechnology)

POSTED

DEADLINE

Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)The National Cancer Institute is inviting grant applications for early-stage development of innovative technologies aimed at advancing cancer research and clinical care through the R61 funding mechanism, which prohibits clinical trials. The focus is on proof-of-concept or pilot studies that demonstrate the technical feasibility of novel tools, assays, platforms, or instruments capable of measuring, analyzing, modeling, or interrogating cancer-related biological systems. Eligible projects must exhibit high technical innovation with the potential to significantly accelerate progress in cancer biology, early detection, diagnosis, treatment, control, or epidemiology. Examples include advanced molecular and cellular analysis systems, multi-omic and spatial profiling methods, next-generation imaging and sensing technologies, immuno-engineering platforms, and improvements in biospecimen handling and quality assessment. While the technologies may have broad applicability, the proposal must center exclusively on cancer-related applications. This opportunity is part of the NCI’s Innovative Molecular Analysis Technologies (IMAT) Program, designed to foster breakthroughs in molecular and analytical methods critical to cancer science. Applications must be submitted under the designated notice, which was posted on July 14, 2026, and falls under the jurisdiction of the Department of Health and Human Services. Prospective applicants should direct inquiries to the IMAT Program Contact listed at nci-imat@nih.gov or by phone at 240-255-0917. The funding opportunity targets early-stage innovation and does not support later-stage development or clinical validation, ensuring resources are allocated to high-risk, high-reward projects that could transform foundational approaches in cancer diagnostics and research.

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

DEADLINE

Tobacco Centers of Regulatory Science (TCORS) (Clinical Trial Optional)The Tobacco Centers of Regulatory Science (TCORS) initiative, anticipated to be released in July 2026 by the National Institutes of Health in collaboration with the Food and Drug Administration’s Center for Tobacco Products, aims to fund multidisciplinary research centers focused on generating scientific evidence to inform tobacco product regulation and advance public health under the Family Smoking Prevention and Tobacco Control Act. These centers must encompass at least three distinct, hypothesis-driven research projects unified by an integrative scientific theme, with each project falling within the regulatory authority of the FDA CTP and addressing one or more key areas such as addiction, behavior, communications, health effects, impact analysis, marketing, product composition and design, or toxicity. Funding for this program will be administered by NIH using resources allocated through the FDA CTP and the FSPTCA, and applications may include clinical trials on an optional basis. The initiative emphasizes collaboration across disciplines to strengthen the evidence base supporting regulatory decision-making. The Tobacco Regulatory Science Program serves as the primary point of contact for inquiries, with all submissions and communications directed through the provided email address. The notice is currently forecasted and not yet open for submission, with no specific application deadline, set-aside classification, or NAICS code published at this stage.

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

DEADLINE